OTIC News and Press, Otonomy Inc. From 06/10/20

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockholders and federal, state and loca...

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for th...

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic T...

Otonomy (NASDAQ: OTIC ): Q1 GAAP EPS of -$0.38 misses by $0.02 . More news on: Otonomy, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended March 31, 2020 and provided an update on its product pip...

The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE: BHVN ) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who ne...

SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic. “Our first priority during this ...

Otonomy, Inc. (OTIC) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Robert Uhl – Westwicke ICR David Weber – President and Chief Executive Officer Paul Cayer – Chief Financial and Business Officer Conference Call Partici...

Otonomy (NASDAQ: OTIC ): Q4 GAAP EPS of -$0.36 beats by $0.08 . More news on: Otonomy, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™  in Ménière’s disease Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Feb. 27, 2020 (GLOBE ...